Sex-dependent compensated oxidative stress in the mouse liver upon deletion of catechol O-methyltransferase

Biochemical Pharmacology

Volumn 77, Issue 9, 2009, Pages 1541-1552

  Tenorio Laranga, Jofre ^a,b   Männistö, Pekka T ^a   Karayiorgou, Maria ^c   Gogos, Joseph A ^c   García Horsman, J Arturo ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

COMT; Dopamine; Oxidative stress; Parkinson's disease; Proteomics

Indexed keywords

CATECHOL METHYLTRANSFERASE; PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; LIVER; MALE; METABOLISM; METABOLITE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; SEX DIFFERENCE; SEX TRANSFORMATION;

ANIMALS; BLOTTING, WESTERN; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENOTYPE; GLUTATHIONE; LIPID PEROXIDATION; LIVER; MALE; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; SEX CHARACTERISTICS;

EID: 63149100897     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.02.004     Document Type: Article

References (91)

1. Forsberg M.M., Juvonen R.O., Helisalmi P., Leppanen J., Gogos J.A., Karayiorgou M., et al. Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 279-289
2. Männistö P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51 (1999) 593-628
3. Jiang H., Xie T., Ramsden D.B., and Ho S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 45 (2003) 1011-1018
4. Xie T., Ho S.L., and Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56 (1999) 31-38
5. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour. Proc Natl Acad Sci USA 95 (1998) 9991-9996
6. Huotari M., Gogos J.A., Karayiorgou M., Koponen O., Forsberg M., Raasmaja A., et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15 (2002) 246-256
7. Huotari M., Santha M., Lucas L.R., Karayiorgou M., Gogos J.A., and Männistö P.T. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 303 (2002) 1309-1316
8. Yavich L., Forsberg M.M., Karayiorgou M., Gogos J.A., and Männistö P.T. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27 (2007) 10196-10209
9. Huotari M., García-Horsman J.A., Karayiorgou M., Gogos J.A., and Männistö P.T. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) 172 (2004) 1-10
10. Babovic D., O'Tuathaigh C.M., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res 183 (2007) 236-239
11. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155 (2008) 1021-1029
12. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 28 (2008) 8709-8723
13. Helkamaa T., Männistö P.T., Rauhala P., Cheng Z.J., Finckenberg P., Huotari M., et al. Resistance to salt-induced hypertension in catechol-O-methyltransferase-gene-disrupted mice. J Hypertens 21 (2003) 2365-2374
14. Tammimäki A., Forsberg M., Karayiorgou M., Gogos J.A., and Männistö P.T. Increase in free choice oral ethanol self-administration in male mice with catechol-O-methyltransferase gene disruption. Basic Clin Pharmacol Toxicol 103 (2008) 297-304
15. Kambur O., Männistö P.T., Viljakka K., Reenilä I., Lemberg K., Kontinen V.K., et al. Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin Pharmacol Toxicol 103 (2008) 367-373
16. Fahn S. Levodopa-induced neurotoxicity-does it represent a problem for the treatment of Parkinson's disease?. CNS Drugs 8 (1997) 376-393
17. Olanow C.W. Oxidation reactions in Parkinsons-disease. Neurology 40 (1990) 32-37
18. Basma A.N., Morris E.J., Nicklas W.J., and Geller H.M. l-Dopa cytotoxicity to Pc12 cells in culture is via its autoxidation. J Neurochem 64 (1995) 825-832
19. Mena M.A., Pardo B., Casarejos M.J., Fahn S., and Deyebenes J.G. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7 (1992) 23-31
20. Michel P.P., and Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic-neurons in culture. J Neurosci Res 26 (1990) 428-435
21. Morel Y., and Barouki R. Repression of gene expression by oxidative stress. Biochem J 342 (1999) 481-496
22. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition-metals, ferritin, glutathione, and ascorbic-acid in Parkinsonian brains. J Neurochem 52 (1989) 515-520
23. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoyagid F., et al. Alterations in glutathione levels in Parkinsons-disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36 (1994) 348-355
24. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., and Marsden C.D. Glutathione-related enzymes in brain in Parkinsons-disease. Ann Neurol 36 (1994) 356-361
25. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., et al. Increased nigral iron content and alterations in other metal-ions occurring in brain in Parkinsons-disease. J Neurochem 52 (1989) 1830-1836
26. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron(Iii) and total iron content in post-mortem substantia nigra of Parkinsonian brain. J Neural Transm 74 (1988) 199-205
27. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in the substantia-nigra of patients with Parkinsons-disease. Neurosci Lett 142 (1992) 128-130
28. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-S170
29. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22 (1999) 123-144
30. Kopin I.J. Catecholamine metabolism-basic aspects and clinical-significance. Pharmacol Rev 37 (1985) 333-364
31. Miller J.W., Selhub J., and Joseph J.A. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 21 (1996) 241-249
32. Nappi A.J., and Vass E. Hydroxyl radical formation via iron-mediated Fenton chemistry is inhibited by methylated catechols. Biochim Biophys Acta 1425 (1998) 159-167
33. Gerlach M., Xiao A.Y., Kuhn W., Lehnfeld R., Waldmeier P., Sontag K.H., et al. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats. J Neural Transm 108 (2001) 189-204
34. Lyras L., Zeng B.Y., McKenzie G., Pearce R.K.B., Halliwell B., and Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 109 (2002) 53-67
35. García-Horsman J.A., Auriola S., and Männistö P.T. Analysis of the proteome of COMT knockout mice. Eur J Pharm Sci 19 (2003) S31-S40
36. Laird P.W., Zijderveld A., Linders K., Rudnicki M.A., Jaenisch R., and Berns A. Simplified mammalian DNA isolation procedure. Nucl Acids Res 19 (1991) 4293
37. Omary M.B., Ku N.O., Tao G.Z., Toivola D.M., and Liao J. "Heads and tails" of intermediate filament phosphorylation: multiple sites and functional insights. Trends Biochem Sci 31 (2006) 383-394
38. Mattow J., Demuth I., Haeselbarth G., Jungblut P.R., and Klose J. Selenium-binding protein 2, the major hepatic target for acetaminophen, shows sex differences in protein abundance. Electrophoresis 27 (2006) 1683-1691
39. Jitrapakdee S., Vidal-Puig A., and Wallace J.C. Anaplerotic roles of pyruvate carboxylase in mammalian tissues. Cell Mol Life Sci 63 (2006) 843-854
40. Chevalier S., Macdonald N., Tonge R., Rayner S., Rowlinson R., Shaw J., et al. Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumour necrosis factor alpha or the peroxisome proliferator nafenopin. Eur J Biochem 267 (2000) 4624-4634
41. Feige J.N., Gelman L., Michalik L., Desvergne B., and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45 (2006) 120-159
42. Ishii Y., Akazawa D., Aoki Y., Yamada H., and Oguri K. Suppression of carbonic anhydrase III mRNA level by an aryl hydrocarbon receptor ligand in primary cultured hepatocytes of rat. Biol Pharm Bull 28 (2005) 1087-1090
43. Parkkila S., Halsted C.H., Villanueva J.A., Väänänen H.K., and Niemelä O. Expression of testosterone-dependent enzyme, carbonic anhydrase III, and oxidative stress in experimental alcoholic liver disease. Dig Dis Sci 44 (1999) 2205-2213
44. Gallagher E.P., Gardner J.L., and Barber D.S. Several glutathione S-transferase isozymes that protect against oxidative injury are expressed in human liver mitochondria. Biochem Pharmacol 71 (2006) 1619-1628
45. Ravichandran V., Seres T., Moriguchi T., Thomas J.A., and Johnston Jr. R.B. S-thiolation of glyceraldehyde-3-phosphate dehydrogenase induced by the phagocytosis-associated respiratory burst in blood monocytes. J Biol Chem 269 (1994) 25010-25015
46. Jacquard C., Trioulier Y., Cosker F., Escartin C., Bizat N., Hantraye P., et al. Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J 20 (2006) 1021-1023
47. Müller A.C., Dairam A., Limson J.L., and Daya S. Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sci 80 (2007) 918-925
48. Comai S., Costa C.V., Ragazzi E., Bertazzo A., and Allegri G. The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in rats. Clin Chim Acta 360 (2005) 67-80
49. Kinoshita M., and Miyata M. Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 36 (2002) 433-438
50. Yokoyama Y., Kuramitsu Y., Takashima M., Iizuka N., Toda T., Terai S., et al. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 4 (2004) 2111-2116
51. Khimani A.H., Mhashilkar A.M., Mikulskis A., O'Malley M., Liao J., Golenko E.E., et al. Housekeeping genes in cancer: normalization of array data. Biotechniques 38 (2005) 739-745
52. Blanquicett C., Johnson M.R., Heslin M., and Diasio R.B. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 303 (2002) 209-214
53. Chen J., Rider D.A., and Ruan R. Identification of valid housekeeping genes and antioxidant enzyme gene expression change in the aging rat liver. J Gerontol A Biol Sci Med Sci 61 (2006) 20-27
54. Ohsawa I., Nishimaki K., Yasuda C., Kamino K., and Ohta S. Deficiency in a mitochondrial aldehyde dehydrogenase increases vulnerability to oxidative stress in PC12 cells. J Neurochem 84 (2003) 1110-1117
55. Britton R.S., O'Neill R., and Bacon B.R. Hepatic mitochondrial malondialdehyde metabolism in rats with chronic iron overload. Hepatology 11 (1990) 93-97
56. Petrak J., Myslivcova D., Man P., Cmejla R., Cmejlova J., and Vyoral D. Proteomic analysis of iron overload in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1059-G1066
57. Pastorelli R., Carpi D., Campagna R., Airoldi L., Pohjanvirta R., Viluksela M., et al. Differential expression profiling of the hepatic proteome in a rat model of dioxin resistance: correlation with genomic and transcriptomic analyses. Mol Cell Proteomics 5 (2006) 882-894
58. Yamaguchi M. Role of regucalcin in calcium signaling. Life Sci 66 (2000) 1769-1780
59. Lanfear J., Fleming J., Walker M., and Harrison P. Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis. Carcinogenesis 14 (1993) 335-340
60. Hoivik D.J., Manautou J.E., Tveit A., Mankowski D.C., Khairallah E.A., and Cohen S.D. Evidence suggesting the 58-kDa acetaminophen binding protein is a preferential target for acetaminophen electrophile. Fundam Appl Toxicol 32 (1996) 79-86
61. Pumford N.R., Hinson J.A., Benson R.W., and Roberts D.W. Immunoblot analysis of protein containing 3-(Cystein-S-Yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice. Toxicol Appl Pharmacol 104 (1990) 521-532
62. Pumford N.R., Martin B.M., and Hinson J.A. A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem Biophys Res Commun 182 (1992) 1348-1355
63. Park J.Y., Seong J.K., and Paik Y.K. Proteomic analysis of diet-induced hypercholesterolemic mice. Proteomics 4 (2004) 514-523
64. Giometti C.S., Liang X., Tollaksen S.L., Wall D.B., Lubman D.M., Subbarao V., et al. Mouse liver selenium-binding protein decreased in abundance by peroxisome proliferators. Electrophoresis 21 (2000) 2162-2169
65. Chu R.Y., Lim H., Brumfield L., Liu H., Herring C., Ulintz P., et al. Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation. Mol Cell Biol 24 (2004) 6288-6297
66. Henkel C., Roderfeld M., Weiskirchen R., Scheibe B., Matern S., and Roeb E. Identification of fibrosis-relevant proteins using DIGE (difference in gel electrophoresis) in different models of hepatic fibrosis. Zeitschrift Fur GastroenterologieZeitschrift Fur Gastroenterologie 43 (2005) 23-29
67. Ku N.O., and Omary M.B. Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation. J Biol Chem 276 (2001) 26792-26798
68. Stumptner C., Omary M.B., Fickert P., Denk H., and Zatloukal K. Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a Mallory body mouse model. Am J Pathol 156 (2000) 77-90
69. Omary M.B., and Ku N.O. Intermediate filament proteins of the liver: emerging disease association and functions. Hepatology 25 (1997) 1043-1048
70. Denk H., Stumptner C., and Zatloukal K. Mallory bodies revisited. J Hepatol 32 (2000) 689-702
71. Ku N.O., Michie S.A., Soetikno R.M., Resurreccion E.Z., Broome R.L., and Omary M.B. Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice. J Cell Biol 143 (1998) 2023-2032
72. Zatloukal K., Stumptner C., Lehner M., Denk H., Baribault H., Eshkind L.G., et al. Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form mallory bodies. Am J Pathol 156 (2000) 1263-1274
73. Ku N.O., Liao J., Chou C.F., and Omary M.B. Implications of intermediate filament protein phosphorylation. Cancer Metastasis Rev 15 (1996) 429-444
74. Cadrin M., Anderson N.M., Aasheim L.H., Kawahara H., Franks D.J., and French S.W. Modifications in cytokeratin and actin in cultured liver-cells derived from griseofulvin-fed mice. Lab Invest 72 (1995) 453-460
75. Salmhofer H., Rainer I., Zatloukal K., and Denk H. Posttranslational events involved in griseofulvin-induced keratin cytoskeleton alterations. Hepatology 20 (1994) 731-740
76. Gopalakrishna R., and Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 28 (2000) 1349-1361
77. Kass G.E.N., Duddy S.K., and Orrenius S. Activation of hepatocyte protein kinase-C by redox-cycling quinones. Biochem J 260 (1989) 499-507
78. Ohshiro Y., Ma R.C., Yasuda Y., Hiraoka-Yamamoto J., Clermont A.C., Isshiki K., et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-Null mice. Diabetes 55 (2006) 3112-3120
79. Dekker L.V., Leitges M., Altschuler G., Mistry N., McDermott A., Roes J., et al. Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. Biochem J 347 (2000) 285-289
80. Mitchell A.E., Morin D., Lakritz J., and Jones A.D. Quantitative profiling of tissue- and gender-related expression of glutathione S-transferase isoenzymes in the mouse. Biochem J 325 (1997) 207-216
81. Jornot L., and Junod A.F. Hyperoxia, unlike phorbol ester, induces glutathione peroxidase through a protein kinase C-independent mechanism. Biochem J 326 (1997) 117-123
82. Pinkus R., Weiner L.M., and Daniel V. Role of quinone-mediated generation of hydroxyl radicals in the induction of glutathione-S-transferase gene-expression. Biochemistry 34 (1995) 81-88
83. Raza H., Robin M.A., Fang J.K., and Avadhani N.G. Multiple isoforms of mitochondrial glutathione S-transferases and their differential induction under oxidative stress. Biochem J 366 (2002) 45-55
84. Gieseg S.P., Simpson J.A., Charlton T.S., Duncan M.W., and Dean R.T. Protein-bound 3,4-dihydroxyphenylalanine is a major reductant formed during hydroxyl radical damage to proteins. Biochemistry 32 (1993) 4780-4786
85. Rodgers K.J., Hume P.M., Morris J.G.L., and Dean R.T. Evidence for l-dopa incorporation into cell proteins in patients treated with levodopa. J Neurochem 98 (2006) 1061-1067
86. Ozawa K., Headlam M.J., Mouradov D., Watt S.J., Beck J.L., Rodgers K.J., et al. Translational incorporation of L-3,4-dihydroxyphenylalanine into proteins. FEBS J 272 (2005) 3162-3171
87. Rodgers K.J., Hume P.M., Dunlop R.A., and Dean R.T. Biosynthesis and turnover of DOPA-containing proteins by human cells. Free Radic Biol Med 37 (2004) 1756-1764
88. Nelson M., Foxwell A.R., Tyrer P., and Dean R.T. Protein-bound 3,4-dihydroxy-phenylanine (DOPA), a redox-active product of protein oxidation, as a trigger for antioxidant defences. Int J Biochem Cell Biol 39 (2007) 879-889
89. Hanlon P.R., Ganem L.G., Cho Y.C., Yamamoto M., and Jefcoate C.R. AhR- and ERK-dependent pathways function synergistically to mediate 2,3,7,8-tetrachlorodibenzo-p-dioxin suppression of peroxisome proliferator-activated receptor-gamma1 expression and subsequent adipocyte differentiation. Toxicol Appl Pharmacol 189 (2003) 11-27
90. Kanasaki K., Palmsten K., Sugimoto H., Ahmad S., Hamano Y., Xie L., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 4531117-4531121
91. Banerjee S., Randeva H., and Chambers A.E. Mouse models for preeclampsia: disruption of redox-regulated signaling. Reprod Biol Endocrinol 7 (2009) 4